Inclusion Criteria:  Diagnosed with relapsed and refractory CD7 + T cell hematologic malignancies (including, but not limited to, T-cell leukemia, extranodal NK/ T-cell lymphoma nasal, peripheral T-cell lymphoma, enteropathy associated T-cell lymphoma and anaplastic T-cell lymphoma, etc.); No alternative treatment options deemed by investigator; Measurable or detectble disease at time of enrollment; Age 18-70 years old, no gender and race limited; Eastern cooperative oncology group (ECOG) performance status of ≤2; Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO); Estimated life expectancy > 12 weeks deemed by investigator; Serum creatinine ≤ 1.5 upper limit of normal (ULN); Serum ALT/ AST ≤ 5 upper limit of normal (ULN); Signed informed consent form (ICF).  Exclusion Criteria:  Women in pregnancy or lactation; Uncontrolled infection; Active hepatitis B virus or hepatitis C virus infection; Concurrent use of corticosteroids or other immunosuppressant medications for chronic disease; Prior treatment with an allogeneic stem cell transplant within 100 days; Grade 2-4 Active graft versus host disease; History of HIV infection; With central nervous system involvement; Patients combine with other disease cause neutrophil count (ANC) < 750/uL or PLT< 50,000/uL.